This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products.
Danaher Partners With AstraZeneca to Support Precision Medicine
by Zacks Equity Research
DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient selection and making advanced tests accessible worldwide.
CVS or DHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CVS vs. DHR: Which Stock Is the Better Value Option?
Why Is Danaher (DHR) Down 4.8% Since Last Earnings Report?
by Zacks Equity Research
Danaher (DHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Consider Retaining Danaher Stock Now
by Zacks Equity Research
DHR gains from strength across its businesses, acquired assets and shareholder-friendly policies. High long-term debt remains concerning.
CVS vs. DHR: Which Stock Is the Better Value Option?
by Zacks Equity Research
CVS vs. DHR: Which Stock Is the Better Value Option?
BLCO or DHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BLCO vs. DHR: Which Stock Is the Better Value Option?
Danaher Q1 Earnings Beat Estimates, Life Sciences Sales Down Y/Y
by Zacks Equity Research
DHR's first-quarter sales decrease 1% year over year, due to the lackluster performance of its Life Sciences and Biotechnology segments.
Danaher (DHR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Danaher (DHR) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Danaher (DHR) delivered earnings and revenue surprises of 16.05% and 3.34%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Danaher Gears Up to Post Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
DHR's first-quarter earnings are likely to have been aided by strength in the Biotechnology segment. However, weakness in the Diagnostics and Life Sciences segments are expected to have hurt.
Exploring Analyst Estimates for Danaher (DHR) Q1 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Danaher (DHR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Danaher (DHR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Danaher Gains From Strength in the Diagnostics Unit Amid Headwinds
by Zacks Equity Research
DHR is poised to gain from strength in the clinical diagnostics business, the Abcam buyout and shareholder-friendly policies. Softness in Life Sciences and Biotechnology units remains a concern.
Top Analyst Reports for Amazon, Oracle & Merck
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Oracle Corp. (ORCL) and Merck & Co., Inc. (MRK).
Parker-Hannifin Benefits From Business Strength Amid Risks
by Zacks Equity Research
PH gains from business strength, strong product portfolio and shareholder-friendly moves. However, challenging conditions in off-highway and transportation markets remain concerning.
Here's Why You Should Avoid Betting on Danaher Stock Right Now
by Zacks Equity Research
Persistent softness in the Life Sciences segment weighs on DHR's performance. An increase in operating expenses is an added concern.
Why Is Cencora (COR) Up 3.1% Since Last Earnings Report?
by Zacks Equity Research
Cencora (COR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Danaher (DHR) Down 7.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Danaher (DHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Danaher Rewards Shareholders With 18.5% Dividend Increase
by Zacks Equity Research
DHR's measures to consistently reward shareholders through dividends and share buybacks hold promise.
Zacks Earnings Trends Highlights: Royal Caribbean and Danaher
by Zacks Equity Research
Royal Caribbean and Danaher are part of the Zacks Earnings Trends article.
Broad-Based Sector Growth Expected for 2025
by Sheraz Mian
2025 is expected to have all 16 Zacks sectors enjoy earnings growth, with eight expected to produce double-digit growth. But what else should investors know?
Broad-Based Sector Growth Expected for 2025
by Sheraz Mian
2025 is expected to have all 16 Zacks sectors enjoy earnings growth, with eight expected to produce double-digit growth. But what else should investors know?
Danaher Q4 Earnings Miss Estimates, Life Sciences Sales Rise Y/Y
by Zacks Equity Research
DHR's fourth-quarter sales increase 2.1% year over year, benefiting from the solid performance of its Life Sciences and Biotechnology segments.
Danaher (DHR) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Danaher (DHR) Lags Q4 Earnings Estimates
by Zacks Equity Research
Danaher (DHR) delivered earnings and revenue surprises of -1.38% and 1.22%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?